tics Concepts Inc. and Smith & Nephew, which represent the first $1.0 billion product segment in the wound care market. Based on these trends and needs, wound healing agents designed to accelerate the rate of wound healing are expected to play a more prominent role in the future of advanced wound care. As reported by MedTech Insight
, the wound care market is projected to experience double digit growth over the next 3 to 5 years, with advanced wound care products comprising the fastest growing segment of the total wound care market. There are an estimated 91.3 million wounds in the U.S., which include 67.0 million surgical wounds, 17.6 million trauma wounds including burn injuries, amputations and traumatic wounds, 2.5 million pressure ulcers, 3.6 million diabetic ulcers and 3.3 million venous stasis and arterial ulcers. The ability to effectively address even a small proportion of these wounds would represent major new market opportunities for application of Tissue Repair's GAM technology.
Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications.
Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. For more information about Cardium's InnerCool subsidiary and patient temperature modulation, including InnerCool's new RapidBlue(TM) System, which recently received FDA clearance, and its CoolBlue(TM) System, Page: 1 2 3 4 5 6 7 8 Related medicine news :1
. An international first at the CHUM - Promising treatment in regeneration of the myocardium through the use of stem cells2
. Cardium Reports on Recent Highlights and Financial Results3
. Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems4
. Cardium Announces InnerCools Endovascular Cooling to be Featured on Science Channels Series Cool Stuff: How It Works5
. Cardium Completes $6.0 Million Financing6
. Cardium Announces Investor Presentation and Corporate Update Webcast7
. Cardium Reports on New York Citys Adoption of Therapeutic Cooling Protocols for Cardiac Arrest Patients8
. Cardium Reports on Exchange Listing With NYSE Alternext US9
. Cardiums InnerCool Announces Launch of New Enhanced Website10
. Cardiums InnerCool Reports on Expanding Use of Therapeutic Hypothermia11
. Cardiums Exchange Listing Compliance Plan Accepted by NYSE Alternext US